IMIM - Institut Hospital del Mar d'Investigacions Mèdiques IMIM - Institut Hospital del Mar d'Investigacions Mèdiques

News

  • 15/06/2016 - Press release

    BIB launches its website to boost visibility of catalan bioinformatic potential

    Bioinformatics Barcelona Association (BIB) launches its websitewww.bioinformaticsbarcelona.eu, which aims to be a reference in the bioinformatic sector at national and international level, and to become the platform for communication and interaction among BIB's partners. Through this website, the association has enhanced its digital presence to become a meeting-point facilitator of initiatives and a think tank for the bioinformatic community. The portal contains sections on the BIB partners and their research groups in the bioinformatic field, and on education and training, job offers and internships, news, activities and news clipping, as well as a section with specific information on the association itself. The website aims to boost the international visibility of our ready-and-available bioinformatic strength, which, through collaboration among partners and together with external agents, can extend current limits to achieve increasingly ambitious goals.

    Més informació "BIB launches its website to boost visibility of catalan bioinformatic potential"

  • 07/06/2016 - Press release

    Clinical trial opens new avenues for pharmacological therapy in Down’s syndrome

    A team of scientists led by doctors Rafael de la Torre at Hospital del Mar Medical Research Institute (IMIM) and Mara Dierssen at the Centre for Genomic Regulation (CRG) have shown that epigallocatechin gallate together with a cognitive stimulation protocol, might improve some cognitive domains in individuals with Down’s syndrome.   The results of the phase 2 study will be published on 6th June in the prestigious journal The Lancet Neurology. The findings suggest that participants who had received the treatment had better scores in the visual memory recognition and inhibition tasks, and improvement in adaptive behaviour than those in the control group (placebo and cognitive training). Though not a cure, this is the first time that a treatment has shown some effectiveness in this syndrome, and it opens the door to new research geared towards treating what was believed to be orphan of treatment.

    Més informació "Clinical trial opens new avenues for pharmacological therapy in Down’s syndrome"

  • 26/05/2016 - Press release

    European project eTOX launches a new video

    When bringing to market any new drug efficiency and safety are essential. R+D Departments in pharmaceutical companies spend lots of efforts to make sure the new compounds meet the highest standards. In the process, large amounts of useful information are produced, that traditionally end up buried in the archives of pharmaceutical companies. Committed to avoiding duplicating processes, wasting time and resources, 13 pharmaceutical industries, 7 academic institutions and 5 SMEs launched the eTOX project. The result of the project will be a comprehensive database with toxicity studies for thousands of drugs (or drug candidates) and a collection of original software applications for toxicity prediction. 

    Més informació "European project eTOX launches a new video"

  • 26/04/2016 - Press release

    A new genetic test improves and expands the detection of mutations that cause resistance to colon cancer treatments

    The expansion of the genetic test allows the detection of newly identified mutations by a team of oncologists at Hospital del Mar and the IMIM that explain a further 10-15% of the resistance to a group of drugs developed by colorectal tumours The resistance caused by EGFR mutations described by the same team of oncologist has been shown to be important in more of 25% of the patients treated using anti-EGFR therapy This work is a clear example of how in just a short time the results of a research project have been transferred to industry, in this case the Belgian multinational Biocartis, and how they have an almost immediate application in patients, improving and personalising colon cancer treatments The patent for the first test was obtained in 2013, the detection kit was marketed in 2014, and it has now been expanded, with a new licence, to include the newly-detected mutations

    Més informació "A new genetic test improves and expands the detection of mutations that cause resistance to colon cancer treatments"

  • 31/03/2016 - Press release

    Hospital del Mar and Vall d'Hebron take part in the biggest international genomic study into strokes

    The Hospital del Mar Medical Research Institute and the Vall d'Hebron Research Institute, in collaboration with the MútuaTerrassa Foundation, were the only Spanish research centres to participate in the largest study to date into genome association with ischaemic stroke, and which involved around 38,000 patients and 400,000 control subjects. The study, published recently in Lancet Neurology by two international consortia, has led to the identification of a gene implicated in atherothrombotic ischaemic stroke. The team of Dr. Jordi Jiménez-Conde, head of the Genetics Area within the Neurovascular Research Group at the IMIM and a neurologist at the Hospital del Mar, took part in the discovery phase of the study. This first part involved the analysis of nearly 900 samples from stroke patients and 1200 controls from the Hospital del Mar, this being the second-ranked centre internationally according number of cases.

    Més informació "Hospital del Mar and Vall d'Hebron take part in the biggest international genomic study into strokes"

  • 1/03/2016 - Press release

    Regulating neuronal membrane lipids could be the key to Alzheimer's and Parkinson's

    A study published in the prestigious journal Scientific Reports from the Nature group demonstrates, for the first time and using computational tools, that polyunsaturated lipids can alter the binding rate of two types of receivers involved in certain nervous system diseases. The work was led by members of the Research Programme on Biomedical Informatics at the IMIM (Hospital del Mar Medical Research Institute) and Pompeu Fabra University as well as researchers from the University of Tampere (Finland), and also involved scientists from the University of Barcelona. Using latest-generation molecular simulations, which are like “computational microscopes”, the researchers have demonstrated that a decrease in polyunsaturated lipids in neuronal membranes, as seen in Parkinson's and Alzheimer's sufferers, directly affects the binding rate of dopamine and adenosine receptors. 

    Més informació "Regulating neuronal membrane lipids could be the key to Alzheimer's and Parkinson's"

  • 11/02/2016 - Press release

    People with mental disorders have an increased risk of developing chronic physical diseases

    People with anxiety disorders have an increased risk of suffering chronic diseases such as heart disease, chronic pain, and peptic ulcers. This is one of the conclusions of a new study published in JAMA Psychiatry, led by the University of Otago (New Zealand) and involving Dr Jordi Alonso, director of the Epidemiology and Public Health programme at the Hospital del Mar Medical Research Institute (IMIM) and a CIBERESP researcher. The study found that all kinds of mental health disorders, related to mood, anxiety, and impulse control, as well as substance use disorders, are associated with an increased risk of a wide range of chronic physical diseases. The researchers studied the relationship between mental disorders and ten diseases: arthritis, chronic pain, heart disease, stroke, hypertension, diabetes, asthma, chronic lung disease, peptic ulcers, and cancer.

    Més informació "People with mental disorders have an increased risk of developing chronic physical diseases"

  • 08/02/2016 - Press release

    New type 2 diabetes biomarker identified

    Researchers from the Hospital del Mar Medical Research Institute (IMIM) have found an epigenetic mechanism implicated in the regulation of blood sugar. The study, published in the journal Molecular Human Genetics, reveals that the methylation of the TXNIP gene is associated with diabetes mellitus type 2 and, in particular, average blood glucose levels. These results, replicated in two patient cohorts, could help to both identify patients at risk of developing diabetes and control treatment response, as well as generating possible future therapies for this disease, one of the major cardiovascular risk factors in the population. The work was coordinated by Carolina Soriano, from the Neurovascular research group at the IMIM, and Jordi Jiménez Conde, from the same group and a neurologist at the Hospital del Mar, in collaboration with the IMIM's Cardiovascular Epidemiology and Genetics group. 

    Més informació "New type 2 diabetes biomarker identified"

  • 27/01/2016 - Press release

    Spending more on food is associated with a healthier diet and weight

    According to an epidemiological study carried out by researchers at the Hospital del Mar Medical Research Institute (IMIM), increasing the money you spend on food is linked to a better quality diet, particularly increased consumption of fruit and vegetables, leading to a healthier weight and decreased risk of cardiometabolic diseases like obesity, diabetes, and cardiovascular problems. The researchers monitored a group of 2181 Spanish men and women aged 25 to 74, all part of the REGICOR (Registre Gironí del Cor) programme, for a period of ten years. They measured their height and weight, and recorded dietary data obtained from a scientifically validated food frequency questionnaire. The average food cost was calculated using official government data.

    Més informació "Spending more on food is associated with a healthier diet and weight"

  • 18/01/2016 - Press release

    A novel brain mechanism for nicotine addiction

    Researchers from the Hospital del Mar Medical Research Institute (IMIM) in collaboration with scientists from Pompeu Fabra University, the Pasteur Institute andPierre and Marie Curie University, have discovered a crucial neural mechanism that explains the process of nicotine reward and addiction. Nicotine, the principal psychoactive component of tobacco, is quickly absorbed through the nasal, oral and respiratory membranes and takes 7 seconds to reach the brain where the receptors are located. It is there where it acts on the central nervous system as well as the autonomic nervous system. This almost immediate relationship between the inhalation of the smoke and its effect at a cerebral level is one of the factors contributing to the highly addictive nature of nicotine. This is explained by the fact that the nicotine exerts its psychopharmacological effects by activating receptors that are very abundant in several specific regions of the brain, the nicotinic acetylcholine receptors (nAChR).

    Més informació "A novel brain mechanism for nicotine addiction"

Contact

Head of Communications:
Rosa Manaut(ELIMINAR)

Communications office:
Marta Calsina(ELIMINAR)

Tel:
(+34) 93 316 06 80
(+34) 699 094 833

Doctor Aiguader, 88
08003 Barcelona

© Institut Hospital del Mar
d'Investigacions Mèdiques
Legal Notice and Privacy Policy | Cookie Policy | Site Index | Accessibility | Find Us | Contact